Centers for Disease Control and Prevention.
Pediatrics. 2008 Nov;122(5):1127-34. doi: 10.1542/peds.2008-2175.
Universal HIV testing of pregnant women in the United States is the key to prevention of mother-to-child transmission of HIV. Repeat testing in the third trimester and rapid HIV testing at labor and delivery are additional strategies to further reduce the rate of perinatal HIV transmission. Prevention of mother-to-child transmission of HIV is most effective when antiretroviral drugs are received by the mother during her pregnancy and continued through delivery and then administered to the infant after birth. Antiretroviral drugs are effective in reducing the risk of mother-to-child transmission of HIV even when prophylaxis is started for the infant soon after birth. New rapid testing methods allow identification of HIV-infected women or HIV-exposed infants in 20 to 60 minutes. The American Academy of Pediatrics recommends documented, routine HIV testing for all pregnant women in the United States after notifying the patient that testing will be performed, unless the patient declines HIV testing ("opt-out" consent or "right of refusal"). For women in labor with undocumented HIV-infection status during the current pregnancy, immediate maternal HIV testing with opt-out consent, using a rapid HIV antibody test, is recommended. Positive HIV antibody screening test results should be confirmed with immunofluorescent antibody or Western blot assay. For women with a positive rapid HIV antibody test result, antiretroviral prophylaxis should be administered promptly to the mother and newborn infant on the basis of the positive result of the rapid antibody test without waiting for results of confirmatory HIV testing. If the confirmatory test result is negative, then prophylaxis should be discontinued. For a newborn infant whose mother's HIV serostatus is unknown, the health care professional should perform rapid HIV antibody testing on the mother or on the newborn infant, with results reported to the health care professional no later than 12 hours after the infant's birth. If the rapid HIV antibody test result is positive, antiretroviral prophylaxis should be instituted as soon as possible after birth but certainly by 12 hours after delivery, pending completion of confirmatory HIV testing. The mother should be counseled not to breastfeed the infant. Assistance with immediate initiation of hand and pump expression to stimulate milk production should be offered to the mother, given the possibility that the confirmatory test result may be negative. If the confirmatory test result is negative, then prophylaxis should be stopped and breastfeeding may be initiated. If the confirmatory test result is positive, infants should receive antiretroviral prophylaxis for 6 weeks after birth, and the mother should not breastfeed the infant.
在美国,对孕妇进行普遍的艾滋病毒检测是预防母婴传播艾滋病毒的关键。在孕晚期进行重复检测以及在分娩时进行快速艾滋病毒检测是进一步降低围产期艾滋病毒传播率的额外策略。当母亲在孕期接受抗逆转录病毒药物治疗,并持续至分娩,然后在婴儿出生后也给予用药时,预防母婴传播艾滋病毒最为有效。即使在婴儿出生后不久开始预防用药,抗逆转录病毒药物也能有效降低母婴传播艾滋病毒的风险。新的快速检测方法可在20至60分钟内识别出感染艾滋病毒的女性或接触过艾滋病毒的婴儿。美国儿科学会建议,在美国,在告知患者将进行检测后,对所有孕妇进行有记录的常规艾滋病毒检测,除非患者拒绝艾滋病毒检测(“选择退出”同意或“拒绝权”)。对于当前孕期艾滋病毒感染状况不明的临产妇女,建议使用快速艾滋病毒抗体检测进行即时产妇艾滋病毒检测,并采用选择退出同意方式。艾滋病毒抗体筛查试验阳性结果应以免疫荧光抗体或蛋白印迹法进行确认。对于快速艾滋病毒抗体检测结果呈阳性的女性,应根据快速抗体检测的阳性结果立即对母亲和新生儿给予抗逆转录病毒预防用药,而无需等待艾滋病毒确认检测结果。如果确认检测结果为阴性,则应停止预防用药。对于母亲艾滋病毒血清学状态未知的新生儿,医护人员应在母亲或新生儿身上进行快速艾滋病毒抗体检测,检测结果应在婴儿出生后12小时内报告给医护人员。如果快速艾滋病毒抗体检测结果呈阳性,应在出生后尽快但肯定要在分娩后12小时内开始抗逆转录病毒预防用药,等待完成艾滋病毒确认检测。应建议母亲不要母乳喂养婴儿。鉴于确认检测结果可能为阴性,应向母亲提供立即开始手动挤奶以刺激乳汁分泌的帮助。如果确认检测结果为阴性,则应停止预防用药并可开始母乳喂养。如果确认检测结果为阳性,婴儿应在出生后接受6周的抗逆转录病毒预防用药,母亲不应母乳喂养婴儿。